Answers are grounded in this paper and cite their sources.
Deep learning (DL) refers to the use of deep artificial neural networks to analyze complex data.DL is the most widely used artificial intelligence (AI) method and is increasingly employed across various sectors of our society, including clinical and translational research.[1] Specifically, DL methods have substantial capabilities in the handling of complex and unstructured data, such as medical images and text data.Primary liver cancer, with HCC encompassing about 80%-90% of cases, is a substantial global health burden and there is a critical need for improved early detection, proper prognostication, and treatment algorithms.[2] Recent evidence suggests that DL could support liver cancer management from early diagnosis to patient stratification and treatment selection.[1,3] However, research results cannot be directly used in clinical routine.Integrating AI into liver cancer treatment is complex because it must address both chronic liver disease and cancer.The evolving nature of these diseases often leads to discrepancies between AI training data and real-world applications, posing a challenge to the effective deployment of AI applications.[4] AI methods are medical devices that require clearance or approval by the Food and Drug Administration (FDA) in the United States of America, and Conformité Européenne (CE)-marking after assessment under the Medical Device Regulation (for radiologybased approaches) or In Vitro Diagnostics Regulation (for histopathology-based approaches) in the European Union.The European Commission has recently agreed on the AI Act, which establishes a systematic regulation of AI applications based on risk assessment.This regulation aims to ensure the safety of AI applications, including those used in health care.Only very few AI methods from academic research have successfully transitioned, or are close to transitioning, into clinical routine.This observation is not necessarily alarmingafter all, only very few molecular biology studies are transitioning to approved pharmaceuticals for clinical use.However, it would be clearly desirable to have a higher number of academic AI methods ultimately implemented for the benefit of patients.Diseases such as breast cancer or prostate cancer have seen clinical approval of many AI methods in the last 5 years, while AI for HCC lags behind these other areas.Creating a potent AI application demands meticulous planning, from identifying the core issue, outlining its scope, to data collection, model development, and testing as well as subsequent regulatory approval and clinical evaluation (Figure 1).To provide a systematic overview of approved AI products, we queried the official FDA database for AI and machine learning (ML)-enabled medical devices.[5] In the database, 77% of all AI/ML-based devices are listed in radiology, and <1% are listed in the field of gastroenterology.
No takes yet. Share an insight, caveat, or question.
Wiest et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: